Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer

Published:2020-09 Issue:5 Volume:21 Page:e435-e444
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Naidoo Jarushka,Nishino Mizuki,Patel Sandip Pravin^ORCID,Shankar Bairavi,Rekhtman Natasha,Illei Peter,Camus Phillipe

Funder

AstraZeneca

Merck

Merck Investigator Studies Program

Canon Medical Systems

NIH

Bristol-Myers Squibb

Eli Lilly

Fate

Incyte

Pfizer

Roche

Xcovery

Fate Therapeutics

Genocea

Iovance

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference89 articles.

1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer;Auperin;J Clin Oncol,2010

2. Locally-advanced non–small cell lung cancer: shall immunotherapy be a new chance?;Filippi;J Thorac Dis,2018

3. Therapeutic management options for stage III non–small cell lung cancer;Yoon;World J Clin Oncol,2017

4. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non–small-cell lung cancer: KCSG-LU05-04;Ahn;J Clin Oncol,2015

5. Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non–small-cell lung cancer;Bradley;J Clin Oncol,2020

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review);Experimental and Therapeutic Medicine;2024-07-30

2. Clinical characteristics and prognosis of pancreatitis associated with immune checkpoint inhibitors;Clinical and Translational Oncology;2024-07-12

3. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study;Journal of Thoracic Oncology;2024-06

4. Drug-induced Lung Disease in the Oncology Patient;Clinics in Chest Medicine;2024-06

5. Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons;Cancers;2024-05-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3